Licensing-in & Licensing-out Projects

A. Licensing-in interests

With years of open-police, Chinese pharmaceutical industry has experienced rapid progress of development. Now it is becoming an attractive market for many players with international strategy basis. Datang is dedicating to the formulation in-licensing process to China market

In EU, USA and other selected countries, Datang is looking for generical or patented formulation for in-licensing in following areas:

Oncology
Cardiovascular
Central Nervous System
Metabolism

Please contact:

David He
Manager, Business Development

Phone: + 86-571-8603 9792
Fax: + 86-571-87858383
E-Mail: davidhe@dtpharmachem.com


B. Licensing-out offers

Datang is representative of FIS Group for the commercialization of its API in China and certain parts of the world.

API (Active Pharmaceutical Ingredients) Category:

CHLORDIAZEPOXIDE DMF 467
CLOMIPHENE CITRATE DMF 5674
OXCARBAZEPINE DMF 16597
CARBAMAZEPINE DMF 6641
CLONAZEPAM DMF 7505
CLOTRIMAZOLE DMF 7548
DIAZEPAM DMF 3164
DILTIAZEM HYDROCHLORIDE DMF 7908
ESTAZOLAM DMF 11784
FLURAZEPAM DIHYDROCHLORIDE DMF 5282
FUROSEMIDE DMF 3512
INDOMETHACIN DMF 3136
LORAZEPAM DMF 5027
NITROFURANTOIN DMF 453
OXAZEPAM DMF 5208
PENTAZOCINE DMF 3776
PIROXICAM DMF 7130
PRAZEPAM DMF 5776
TEMAZEPAM DMF 5223

For more products, please refer to FIS Group website: www.fisvi.com.

Please contact:

David He
Manager, Business Development

Phone: + 86-571-8603 9792
Fax: + 86-571-87858383
E-Mail: davidhe@dtpharmachem.com